In fact, uPAR and CXCR4 expression in AML varies according to the FAB subtype (highest expression in M5 and lowest in M0) 21,22,25, thus leukaemia cells seemed a suitable system to validate the expression and function of identified miRs. This evidence concerns the gene CXCR4 and acute myeloid leukemia.